EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte Studie

Whole‐body and targeted narrowband ultraviolet B phototherapy effectively stabilize acral vitiligo with negligible repigmentation beyond wrists and ankles: Results from a split‐body randomized controlled trial

Anish Thind iD, Keshavamurthy Vinay iD, Hitaishi Mehta, Anuradha Bishnoi, Muthu Sendhil Kumaran, Davinder Parsad

Photodermatology, Photoimmunology & Photomedicine · 2024

DOI: 10.1111/phpp.12960 ↗

At a glance

Randomisierte kontrollierte Studie in Photodermatology, Photoimmunology & Photomedicine, 2024. Written by Anish Thind and 5 co-authors. Institution: Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Major MEDLINE topics: Vitiligo, Ultraviolet Therapy. Cited 5 times so far (Crossref); 32 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Narrowband ultraviolet B (NB‐UVB) phototherapy promotes stability and repigmentation in vitiligo. No studies have compared targeted NB‐UVB with whole‐body NB‐UVB in treatment of acral vitiligo.

Objectives

This randomized split‐body study compared whole‐body NB‐UVB with targeted NB‐UVB in inducing stability and repigmentation in acral vitiligo.

Methods

Thirty‐two patients with bilaterally symmetrical acral vitiligo lesions (distal to elbows and knees) were recruited. Patients received whole‐body NB‐UVB treatment, with one hand and one foot shielded until elbow and knee, followed by targeted NB‐UVB treatment on the shielded side. Patients were assessed at 4‐week intervals for 24 weeks using Vitiligo Disease Activity (VIDA) score, Vitiligo Skin Activity Score (VSAS), Vitiligo Area Scoring Index (determined through fingertip method, using the method to calculate facial‐VASI) and degree of repigmentation.

Results

After 12 weeks, 87.5% of patients achieved a VIDA score of 3, with none having active disease at 24 weeks. Over 50% repigmentation was observed in 42.2% and 37.5% of limbs in whole‐body and targeted groups, respectively ( p = .95). No improvement in F‐VASI scores of hands and feet (distal to wrist and ankles) was noted with either modality over the 24‐week period.

Conclusion

Our study showed comparable repigmentation rates between whole‐body and targeted NB‐UVB groups. Limited effectiveness of phototherapy in repigmentation of hands and feet underscores an important therapeutic gap.

Subjects

MeSH terms (MEDLINE)

VitiligoUltraviolet TherapyHumansWristAnkleTreatment OutcomePhototherapyCombined Modality Therapy

Author keywords

acral vitiligonarrowband ultraviolet Btargeted NB-UVBtargeted phototherapyvitiligo

Authors and institutions

  • Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

ORCID profiles: Anish Thind, Keshavamurthy Vinay

Cite

APA

Thind, A., Vinay, K., Mehta, H., Bishnoi, A., Kumaran, M. S., & Parsad, D. (2024). Whole‐body and targeted narrowband ultraviolet B phototherapy effectively stabilize acral vitiligo with negligible repigmentation beyond wrists and ankles: Results from a split‐body randomized controlled trial. Photodermatology, Photoimmunology & Photomedicine. https://doi.org/10.1111/phpp.12960

Vancouver

Thind A, Vinay K, Mehta H, Bishnoi A, Kumaran MS, Parsad D. Whole‐body and targeted narrowband ultraviolet B phototherapy effectively stabilize acral vitiligo with negligible repigmentation beyond wrists and ankles: Results from a split‐body randomized controlled trial. Photodermatology, Photoimmunology & Photomedicine. 2024. doi:10.1111/phpp.12960

BibTeX
@article{Thind2024,
  author = {Thind, Anish and Vinay, Keshavamurthy and Mehta, Hitaishi and Bishnoi, Anuradha and Kumaran, Muthu Sendhil and Parsad, Davinder},
  title = {Whole‐body and targeted narrowband ultraviolet B phototherapy effectively stabilize acral vitiligo with negligible repigmentation beyond wrists and ankles: Results from a split‐body randomized controlled trial},
  journal = {Photodermatology, Photoimmunology & Photomedicine},
  year = {2024},
  doi = {10.1111/phpp.12960}
}
Start for free →